Recent News

• 09.08.2025 - Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds
• 09.08.2025 - NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults
• 09.03.2025 - Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
• 08.20.2025 - Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan
• 08.12.2025 - Beyond Air® Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
• 07.25.2025 - Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast
• 07.22.2025 - Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.

Recent Filings

• 09.08.2025 - 8-K Current report
• 09.08.2025 - EX-99.1 EX-99.1
• 08.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.18.2025 - 8-K Current report
• 08.18.2025 - EX-99.1 EX-99.1
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.10.2025 - 8-K Current report
• 07.09.2025 - 3 Initial statement of beneficial ownership of securities